• Filing Date: 2021-04-16
  • Form Type: 10-K/A
  • Description: Annual report (Amendment)
v3.21.1
E. STOCKHOLDERS' EQUITY (Details 2)
12 Months Ended
Dec. 31, 2020
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of option shares vested | shares 85,148
Weighted average exercise price vested | $ / shares $ 33.24
Aggregate intrinsic value vested | $ $ 350 [1]
Weighted average remaining contractual life vested 6 years 1 month 6 days
Number of option shares vested and expected to vest | shares 410,888
Weighted average exercise price vested and expected to vest | $ / shares $ 8.09
Aggregate intrinsic value vested and expected to vest | $ $ 207,747 [1]
Weighted average remaining contractual life vested and expected to vest 7 years 9 months 18 days
[1] Amount represents the difference between the exercise price and $1.86, the closing price of Tenax Therapeutics' stock on December 31, 2020, as reported on the Nasdaq Capital Market, for all in-the-money options outstanding.